STUDIO

BioStock Studio: Expres2ion’s CEO gives status update

Biotech ExpreS2ion Biotechnologies - that develops vaccines for covid-19, breast cancer, influenza and malaria - is currently conducting a rights issue of 73 million...
BENT U FRANDSEN

BioStock Investor Pitch: ExpreS2ion Biotechnologies

ELICERA's CSO and Co-founder MAGNUS ESSAND

BioStock Studio: Elicera’s immuno-oncology platform iTANK reaches high-impact journal

Jeppe Øvlesen

BioStock Studio: SynAct Pharma’s CEO on the rights issue and partnering...

BioStock Studio: Alligator Bioscience's CEO on the latest data

BioStock Studio: Alligator Bioscience’s CEO on the latest data

Load more

RECOMMENDED READING

Sprint Bioscience expands collaboration

Sprint Bioscience increases innovation power

Huddinge-based Sprint Bioscience has a long-standing collaboration with Associate Professor Julian Walfridsson to find...
Ultimovacs Q1

Ultimovacs keeps delivering in Q1

Q1 saw Norwegian immuno-oncology company Ultimovacs advance on a number of fronts. The company’s...
Respiratorius to split into two companies

Focus on company split for Respiratorius during Q4

Cominie

CombiGene’s new project manager on a broadened pipeline

Promore Pharma leg wounds

Promore Pharma aims to accelerate healing of venous leg ulcers

Evaxion positive clinical momentum

Evaxion Biotech shows strong clinical momentum in Q1

EVENT

© BioStock 2021